10.95USD+1.91%Mkt Cap: 587.95M USDP/E: —Last update: 2026-06-01
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap587.95M USD
Enterprise Value329.51M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-324.25M USD
Revenue/Share—
Last Price10.95 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees384
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.86
PEG—
EV/EBITDA-1.06
EV/Revenue—
P/S—
P/B1.07
EPS (TTM)-6.32
EPS (Forward)-5.84
52W Range
7.90032% of range17.40
52W High17.40 USD
52W Low7.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.89%
ROA-54.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-188.52M USD
CapEx (TTM)46.74M USD
FCF Margin—
FCF Yield—
Net Debt-257.35M USD
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity-0.29
Current Ratio11.75
Quick Ratio11.37
Book Value/Sh10.17 USD
Cash/Share9.461 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)25.20 USD
Target Range5.000 USD – 34.00 USD
# Analysts5
Ownership
Shares Out.54.14M
Float27.52M
Insiders17.39%
Institutions64.22%
Short Interest
Short Ratio13.4d
Short % Float8.86%
Short % Out.6.67%
Shares Short3.61M
Short (prev mo.)3.56M
Technical
SMA 5010.51 (+4.2%)
SMA 20011.85 (-7.6%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)287.72K
Avg Vol (10d)417.80K
Technical Indicators
RSI (14)50.0
MACD-0.0267
MACD Signal0.0661
MACD Hist.-0.0929
BB Upper13.02 USD
BB Middle10.79 USD
BB Lower8.564 USD
BB Width41.26%
ATR (14)1.045 USD
Vol Ratio (20d)0.43x